



Oral SL Semaglutide FAX Order Form

11161 New Hampshire Ave Ste 110 Silver Spring, MD 20904 ·

PHONE: 301-592-0060 · FAX: 301-592-0054

Have questions? Text us at 301-780-4645

Patient Information		Prescriber Information	
Patient Name		Prescriber Name	
Address Line 1		Phone	
Address Line 2		Company	
City/State/Zip		NPI Number	
Phone		Email Address	
Date of Birth			
Email Address			
Delivery/Pickup			

Sublingual Semaglutide

1 mg/1 ml

Default Directions

Take 0.25 mg dose - 0.25 mL daily x 2 weeks, then 0.5 mg dose - 0.5 mL daily x 4 weeks. If needed, increase to 1 mg dose/1 mL daily. Must place it under the tongue for 5 minutes or longer.

Alternate Directions: _____

Quantity 30 mL

Refills: 5 4 3 2 1



To electronically submit this form, please use our HIPAA-compliant online portal.

Prescriber's Signature:

Date:



Oral SL Semaglutide Information

At little Acorn Pharmacy, we prioritize the highest quality standards for our medications, ensuring trust and reliability in your healthcare. Our Oral Semaglutide, tested rigorously by an independent lab, guarantees efficacy and safety with a shelf-life of 90 days.

Please remember:

- The pharmacy will process the order once all necessary information is provided.
- Payment is due before compounding. We will contact the patient for payment and delivery information
- Prescription orders require verification with the prescribing doctor.
- Insurance coverage is not offered on compounding
- The medication expires after 90 days.
- Free shipping for Maryland and Washington, DC
- E-scribe (1) Select Rybelsus® 14mg tabs then type the following into the signature field: "Compound 1 mg/ 1 ml" and how you want them to take it. Quantity = 30 mL
- Questions? Text us at 301.780.4645 or call us at 301.592.0060.

The FDA does not review any compounded medication from any pharmacy for safety or efficacy. Rybelsus® is a registered trademark of Novo Nordisk A/S. The formula and or statements listed are provided for educational objectives only. Compounded formulations have not been evaluated by the Food and Drug Administration. Formulas and or other materials listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety.

Research On Semaglutide

<p>PCCA SCIENCE</p> <p><u>PCCA SubMagna™ SL HMW Technical Report</u></p> <p>Published 2024</p> <p>Sublingual Semaglutide shows promise as a new patient option, with PCCA Science's recent research highlighting SubMagna's success in absorbing semaglutide through a novel drug delivery system for large molecules. This development marks a significant advancement in semaglutide formulations, potentially overcoming the limitations of injectable and oral versions.</p>	<p>THE NEW ENGLAND JOURNAL OF MEDICINE</p> <p>Once-Weekly Semaglutide in Adults with Overweight or Obesity</p> <p><u>https://www.nejm.org/doi/full/10.1056/NEJMoa2032183</u></p> <p>Published: February 10, 2021</p> <p>In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight</p>	<p>MAYO CLINC</p> <p>Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity</p> <p><u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486455/</u></p> <p>Published: September 19, 2022</p> <p>The results of this cohort study suggest that weekly doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials.</p>
---	--	---